medigraphic.com
Coordinación General de Investigación de la Facultad de Salud Pública y Nutrición y la Dirección General de Sistemas e Informática de la Universidad Autónoma de Nuevo León

2001, Number 4

<< Back Next >>

Rev Salud Publica Nutr 2001; 2 (4)

Evaluación clínica, bioquímica y molecular de una familia con recurrencia de defectos del tubo neural

Martínez VRT, Rojas MA, Sánchez HJG, Hernández TU, Delgado EI, Ortíz LR

Language: Spanish
References: 41
Page:
PDF size: 275.75 Kb.


ABSTRACT

A family is presented it would originate of the south of Nuevo León with recurrence of neural tube defects (NTD) whose products survivors have been achieved after the treatment pre-conceptional with folate. After the clinical, biochemical and molecular evaluations, it is found that the members present heterocigocity for the mutation MTHFR 677T and that the mother and the daughter are compound heterozygotes 677C/677T-1298A/1298C. The levels of red cells folates and plasmatic they are normal and the father only presents slightly increased levels of homocystenaemia. These results suggest an interaction among genetic and nutritional factors previously implied additionally in the pathogenesis of the NTD that could be associate to the recurrrrence of this defect.


REFERENCES

  1. Lemire RJ. Neural tube defects. JAMA1988;259:558-562.

  2. International Centre for Birth Defects, EUROCAT 1998 . World Atlas of Birth Defects. Geneva: World Health Organization; pp. 20-31.

  3. Martínez de Villarreal LE, C Ayala-Alvarado y C Limón-Benavides 1999. Defectos congénitos y mortalidad infantil en el estado de Nuevo León. Medicina Universitaria; 1:113-117.

  4. Villarreal-Pérez JZ, JF González-Guerreo, JI Wong-Rios y LE Martínez de Villarreal 1999. Actualización y reporte sobre los defectos congénitos en el Estado de Nuevo León. Secretaría Estatal de Salud de Nuevo León. Monterrey, México

  5. Wang Y, Y Wu, G Zhou, C Xu and K Xiao 1996. An estimate of recurrence risk for neural tube defects in China. Hua Hsi I Ko Ta Hsueh Hsueh Pao, 27:196-198.

  6. Carter CO and JAF Roberts 1967. The risk of recurrence after two children with central-nervous-system malformations. Lancet; 1:306-308.

  7. van der Put NM, RP Steegers-Theunissen, P Frosst, FJ Trijbels, TK Eskes, LP van den Heuvel, EC Mariman, M den Heyer, R Rozen and HJ Blom.1995. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bífida. Lancet; 346: 1070-1071.

  8. MRC Vitamin study research group. 1991. Prevention of neural-tube defects results of the Medical Reserach Council Vitamin Study. Lancet; 338:131-137.

  9. Czeizel AE and I Dudas 1992. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med; 327:1832-1835.

  10. Kang SS, PW Wong, A Susmano, J Sora, M Norusis and N Ruggie.1991. Thermolabile methylentetrahydrofolate reductase. An inherited risk factor for coronary artery disease. Am J Hum Genet; 48: 536-545.

  11. Engbersen AM, DG Franken, GH Boers, EM Stevens, FJ Trijbels and HJ Blom.1995. Thermolabile 5,10-mehylentetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet; 56:142-150.

  12. Rosenquist TH, SA Ratashak and J Selhub.1996. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc Natl Acad Sci U S A; 93:15227-15232.

  13. Vanaerts LA, HJ Blom, RA Deabreu, FJ Trijbels and TK Eskes.1994. Copius Peereboom-Stegeman JH, Noordhoek J. Prevention of neural tube defects by and toxicity of L-homocysteine in cultured postimplantation rat embryos. Teratology; 50:348-360.

  14. Mutchinick OM, MA Lopez, L Luna, J Waxman and VE Babinsky.1999. High prevalence of the thermolabile methylenetetrahydrofolate reductase variant in Mexico: a country with a very high prevalence of neural tube defects. Mol Genet Metabol; 68:461-467.

  15. van der Put NM, F Gabreels, EM Stevens, JA Smeitink, FJ Trijbels, TK Eskes, LP van den Heuvel and HJ Blom.1998. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet; 62:1044-1051.

  16. Thompson MW, RR Mclnnes y HF Willard. 1996.Thompson & Thompson Genética en Medicina. 4a ed. Barcelona: Masson, SA. p. 337-350.

  17. Wald NJ and A Kennard 1996. Prenatal screening for neural tube defects and Down syndrome. In: Emery and Rimoin’s Principles and Practice of Medical Genetics. [DL Rimoin, JM Connor and RE Pyeritz] Third edition. New York: Churchill-Livingstone; pp. 545-562.

  18. Shaffer LG, ML Marzita, J Bodurtha, A Newlin and WE Nance.1990. Evidence for a major gene in familial anencephaly. Am J Hum Genet; 36:97-101.

  19. International Centre for Birth Defects, Op.cit

  20. Mutchinick OM et. al., Op.cit

  21. van der Put NM, RP Steegers-Theunissen et. al., Op.cit.

  22. Ou CY, RE Stevenson, VK Brown, CE Schwartz, WP Allen, MJ Khoury, R Rozen. GP Oakley Jr and MJ AdamsJr.1996. 5,10 Methylenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects. Am J Med Genet; 63:610-614.

  23. Whitehead AS, P Gallagher, JL Mills, PN Kirke, H Burke, AM Molloy, DG Weir, DC Shields, JM Scott. 1995. A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects. QJM; 88:763-766.

  24. Shields DC, PN Kirke, JL Mills, D Ramsbottom, AM Molloy, H Burke, DG Weir, JM Scott and AS Whitehead.1999. The "thermolabile" variant of methylentetrahydrofolate reductase and neural defect: An evaluation of genetic risk and the relative importance of the genotypes of the embryo and the mother. Am J Hum Genet; 64:1045-1055.

  25. Christensen B, L Arbour, P Tran, D Leclerc, N Sabbaghian, R Platt, BM Gilfix, DS Rosenblatt, RA Gravel, P Forbes and R Rozen 1999. Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J Med Genet; 84:151-157.

  26. Papapetrou C, SA Lynch, J Burn and YH Edwards 1996. Methylenetetrahydrofolate reductase and neural tube defects. Lancet; 348:58.

  27. Wilcken DE and XL Wang 1996. Relevance to spina bifida of mutated methylenetetrahydrofolate reductase. Lancet; 347:340.

  28. Mornet E, F Muller, A Lenvoise-Furet, AL Delezoide, JY Col, B Simon-Bouy and JL Serre 1997 Screening of the C677T mutation on the methylenetetrahydrofolate reductase gene in French patients with neural tube defects. Hum Genet; 100:512-514.

  29. Speer MC, G Worley, JF Mackey, E Melvin, WJ Oakes and TM George.1997. The thermolabile variant of methylenetetrahydrofolate reductase (MTHFR) is not a major risk factor for neural tube defect in American Caucasicans. Neurogenetics; 1:149-150.

  30. de Franchis R, A Buoninconti, C Mandato, A Pepe, MP Sperandeo, R Del Gado, V Capra, E Salvaggio, G Andria and P Mastroiacovo.1998. The C677T mutation of the 5,10-methylenetetrahydrofolate reductase gene is a moderate risk factor for spina bifida in Italy. J Med Genet; 35:1009-1013.

  31. Shaw GM, R Rozen, RH Finnell, CR Wasserman and EJ Lammer.1998. Maternal vitamin use, genetic variation of infant methylenetetrahydrofolate reductase, and risk for spina bifida. Am J Epidemiol; 148:30-31.

  32. Koch MC, K Stegmann, A Ziegler, B Schroter and A. Ermert 1998. Evaluation of the MTHFR C677T allele and the MTHFR gene locus in a German spina bifida population. Eur J Pediatr; 157:487-492.

  33. Ubbink JB, A Christianson, MJ Bester, MI Van Allen, PA Venter, R Delport, HJ Blom HJ, A van der Merwe, H Potgieter and WJ Vermaak 1999. Folate status, homocysteine metabolism, and methylene tetrahydrofolate reductase genotype in rural South African blacks with a history of pregnancy complicated by neural tube defects. Metabolism; 48:269-274.

  34. Boduroglu K, M Alikasifoglu, B Anar and E Tuncbilek 1999. Association of the 677C-->T mutation on the methylenetetrahydrofolate reductase gene in Turkish patients with neural tube defects. J Child Neurol; 14:159-161.

  35. van der Put NM, F Gabreels, et. al. Op. cit.

  36. Idem.

  37. Locksmith GJ and P Duff 1998. Preventing neural tube defects: The importance of the periconcepcional folic acid supplement. Obstet Gynecol; 91:1027-1034.

  38. van der Put NM, F Gabreels, et. al. Op. cit.

  39. Frosst P, HJ Blom, R Milos, P Goyette, CA Sheppard, RG Matthews, GJ Boers, M den Heijer, LAKluijtmans, LP van den Heuvel and R Rozen.1995. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Gene ;10:111-113.

  40. Zhao Q, RR Behringer and B de Crombrugghe 1996. Prenatal folic acid treatment suppresses acrania and meroanencephaly in mice mutant for the Cart1 homeobox gene. Nat Genet;13:275-283.

  41. Carter M, S Ulrich, Y Oofuji, DA Williams and ME Ross.1999. Crooked tail (Cd) models human folateresponsive neural tube defects. Hum Mol Genet; 8:2199-2204




2020     |     www.medigraphic.com